A graphene gold nanocomposite-based 5-FU drug and the enhancement of the MCF-7 cell line treatment

RSC Adv. 2019 Oct 2;9(53):31021-31029. doi: 10.1039/c9ra05669f. eCollection 2019 Sep 26.

Abstract

There is no doubt that cancer is now one of the most formidable diseases in the world; despite all the efforts and research, common treatment routes, including chemotherapy, photodynamic therapy, and photothermal therapy, suffer from different limitations in terms of their efficiency and performance. For this reason, different strategies are being explored to improve the efficiency of the traditional drugs reported to date. In this study, we have redirected the function of one of these drugs (5-fluorouracil, 5-FU) by combining it with a graphene-gold nanocomposite in different molar ratios that has been exceedingly used for biological research development. The high activity of the graphene-gold material enables it to produce reactive oxygen and ions, which display good anticancer and antioxidant activity through the scavenging of the DPPH, SOD and GP x radicals; in addition, different characterizations have been used to confirm the structure and morphology of the obtained samples. Highly potent cytotoxicity against the MCF-7 cells was achieved with the drug combination containing the nanocomposite. All the results, including those obtained via cytometry, indicate that the combination of 5% graphene-gold nanocomposites with 5-FU exhibits a higher antitumor impact and more drug stability than pure 5-FU.